BlossomHill Therapeutics (BLSM) vs Kamada (KMDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BlossomHill Therapeutics is the larger company by market cap ($461.2 million vs $446.8 million), about 1.0 times the size. Kamada pays a dividend yielding 7.24%, while BlossomHill Therapeutics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLSM | KMDA |
|---|---|---|
| Share price | $14.51 | $7.74 |
| Market cap | $461.20M | $446.85M |
| 1-day change | +0.69% | -1.15% |
| YTD return | — | +9.63% |
| 1-year return | — | +14.67% |
| 5-year return | — | +22.66% |
| P/E ratio (TTM) | — | 20.37 |
| Forward P/E | — | 13.34 |
| EPS (TTM) | $-10.38 | $0.38 |
| Dividend yield | 0.00% | 7.24% |
| Annual dividend | $0.00 | $0.56 |
| Revenue (latest FY) | — | $180.46M |
| Revenue growth (YoY) | — | +12.12% |
| Net income (latest FY) | — | $20.20M |
| Gross margin | — | 42.34% |
| Operating margin | — | 14.54% |
| Net margin | — | 11.19% |
| 52-week high | $27.99 | $9.35 |
| 52-week low | $11.02 | $6.63 |
| Distance from 52-week high | -48.16% | -17.22% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +143.97% | +77.65% |
| Average volume | 193.15K | 121.87K |
| Shares outstanding | 31.78M | 57.73M |
| Employees | 69 | 462 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Kamada offers a meaningfully higher dividend yield (7.24% vs 0.00%).
About BlossomHill Therapeutics
BLSM stock →BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Kamada
KMDA stock →Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 462 employees
BLSM vs KMDA FAQ
Which is bigger, BlossomHill Therapeutics or Kamada?
BlossomHill Therapeutics (BLSM) is larger, with a market capitalization of $461.20M compared with $446.85M for Kamada (KMDA).
Which pays a higher dividend, BlossomHill Therapeutics or Kamada?
Kamada pays a dividend yielding 7.24%, while BlossomHill Therapeutics does not currently pay a regular dividend.
Are BlossomHill Therapeutics and Kamada in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.